These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29207318)

  • 1. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
    Sakai H; Tsurutani J; Iwasa T; Komoike Y; Sakai K; Nishio K; Nakagawa K
    Breast Cancer; 2018 Sep; 25(5):605-613. PubMed ID: 29700710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
    Wang DS; Liu ZX; Lu YX; Bao H; Wu X; Zeng ZL; Liu Z; Zhao Q; He CY; Lu JH; Wang ZQ; Qiu MZ; Wang F; Wang FH; Li YH; Wang XN; Xie D; Jia WH; Shao YW; Xu RH
    Gut; 2019 Jul; 68(7):1152-1161. PubMed ID: 30269082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
    Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
    EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
    BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
    Nakamura Y; Okamoto W; Kato T; Esaki T; Kato K; Komatsu Y; Yuki S; Masuishi T; Nishina T; Ebi H; Sawada K; Taniguchi H; Fuse N; Nomura S; Fukui M; Matsuda S; Sakamoto Y; Uchigata H; Kitajima K; Kuramoto N; Asakawa T; Olsen S; Odegaard JI; Sato A; Fujii S; Ohtsu A; Yoshino T
    Nat Med; 2021 Nov; 27(11):1899-1903. PubMed ID: 34764486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
    Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
    Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
    Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
    J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
    Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
    Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Sakamoto Y; Nishina T; Inaki K; Kuwahara Y; Wada N; Suto F; Arita T; Sugihara M; Tsuchihashi Z; Saito K; Kojima A; Yamaguchi K
    Nat Med; 2024 Jul; 30(7):1933-1942. PubMed ID: 38745009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer.
    Gao J; Wang H; Zang W; Li B; Rao G; Li L; Yu Y; Li Z; Dong B; Lu Z; Jiang Z; Shen L
    Cancer Sci; 2017 Sep; 108(9):1881-1887. PubMed ID: 28677165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
    Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
    Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
    Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
    Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.